Connect with us


Why MCTC Holdings Inc (OTCMKTS:MCTC) Should be on Your Radar



If there is one micro-cap growth stock that might represent an extremely interesting opportunity right now, we would point to MCTC Holdings Inc (OTCMKTS:MCTC), now doing business now as Cannabis Global, Inc. (MCTC), with an imminent name change now in the works.

This stock jumps out at us right now for two main reasons: first, it is flying under the radar to an almost obscene extent, with a series of potentially huge moves stacking up over the past two months without any real response in the stock, and second, because the company just put out a watershed corporate update – a piece that seems to have gone almost completely unnoticed by the market, but one that effectively announced the start of commercial stage operations. That’s nearly always the most important moment in the life cycle of a publicly traded stock. The hint that we are transitioning from development to commerce is the green light for more engagement with a stock, provided you have reason to believe that the company has a substantive value proposition to market to investors.

MCTC Holdings Inc (OTCMKTS:MCTC) certainly fits that bill.

In its corporate update announcement on Tuesday morning, the company stated directly that it has begun to “transition toward monetization of its market-leading intellectual property involving isolation, infusion, and bio-enhancement of potent cannabinoids.”

That’s very direct language and is exactly what we want to hear. This was further backed up by the company’s management.

“This continues to be a transformative period for Cannabis Global as we start to realize a commercial return on our foundation of strong R&D investments,” commented Arman Tabatabaei, CEO of Cannabis Global. “We strongly believe we have positioned the Company as a market leader in the cannabis, hemp, and CBD products landscape. We have defensible unique IP that is increasingly in demand, as evidenced by our recent licensing deal flow. We anticipate a continued pickup in tangible agreements with downstream partners and distributors.”



What we know about MCTC is that it has genuinely powerful IP that is starting to gain traction through licensing deals that will likely be the company’s bread-and-butter for the first part of its assault on topline growth. In fact, this is already underway, with several deals recently announced, and several more likely in the works.

The model is, for the time being, to deliver superior isolation, infusion, and bio-enhancement of both CBD and THC through the licensing of proprietary methods and trade secrets that the company has developed or acquired over the past year. The company claims to have methods that can simultaneously lower cost and raise quality (bioavailability) for infusing CBD and/or THC into edibles, coffees, or sweeteners.

Given the accelerating deal flow we are seeing for this technology, the California cannabis market would seem to agree. One clear example of that substantive value is its recent deal with BudCars, the top emerging cannabis delivery outfit that just announced an expansion into the LA regional market. BudCars is stacking up massive growth and just signed a deal to license Cannabis Global’s proprietary tech for edibles distribution to its core customer base. BudCars is already on pace to do better than $30 million in annualized 2020 sales.

According to the company, Cannabis Global has recently filed six patents on cannabinoid extraction technologies and delivery systems. Management is currently working with patent counsel to protect various other technologies it has developed or is currently developing, including its programs pertaining to cannabinoid glycosides, polymeric cannabinoid nanoparticles and nanofibers, and its hemp extract-based alcohol replacement technologies.

We would also note that it is now testing a formulation that could provide a cannabinoid solution for weight loss, which could open up a massive new market opportunity.

The main point here is this: MCTC is flying under the radar even as the company takes monumental steps toward major revenue generation based on a foundation of clearly valuable IP with specific application in the monster cannabis structural growth trend.


This article is part of Networks. Read the Networks Disclaimer.


Singlepoint Inc. (OTCMKTS: SING) In A Joint Venture With Box Biosciences To Produce and Distribute Hand Sanitizers



Singlepoint Inc. (OTCMKTS:SING) has formed a joint venture with BOX Biosciences to distribute various hand-sanitizer products produced in Carlsbad, California.

Singlepoint joint venture producing FDA-approved sanitizer

The two companies are distributing the FDA-approved sanitizer products on the west and east coast. BOX Biosciences is headquartered in Charleston, South Carolina, with distribution outlets in Raleigh, North Carolina, and Carlsbad, California. Following the coronavirus outbreak, there has been a shortage of disinfectant and sanitizer products.

Because of the urgent need to fill this shortage, the companies through the joint venture are working to ensure the US is safe by producing bulk hand sanitizers. They will also introduce disinfectants as permitted by the demand of hand sanitizers. Already the companies have on-going sales to various retail outlets, and currently, they are in discussions for potential hand sanitizer product sales.

The sanitizers the companies are manufacturing kill 99.9% of coronavirus causing germs, and they will be available to the general public and essential businesses. For now, the companies have prioritized the sanitizers to nursing homes, clinics, hospitals, government units, and home healthcare agencies. Equally essential businesses will also get prioritized in getting the bulk hand sanitizers.

Singlepoint and Box committed to offering solutions to COVID-19

Ryan Cowell, the founder of BOX Biosciences, indicated that they will focus on bulk orders of 250 gallons, 55-gallon drums, 1 gallon, 1 liter, 32oz, and 8oz totes of sanitizer. For businesses having the ability to offload bulk sanitizer from tankers, they can also order.

Singlepoint and Box’s expansion to making disinfectant and hand sanitizers shows how companies are dedicated to offering significant well-being solutions for the environment, surfaces, and people in response to the COVID-19 outbreak.

BOX’s operations manager Troy Lorenz stated there is an urge by businesses and people to clean and disinfect their work environment, and as a result, the products they are producing are important for the environment and people. The objective of Singlepoint and Box is to help authorities and people in combating the spread of COVID-19.

Continue Reading


Sproutly Canada Inc (OTCMKTS:SRUTF) Chalks Out A Business Strategy To Focus On Commercialization Of APP Technology



Sproutly Canada Inc (OTCMKTS:SRUTF) has chalked out a business transformation strategy to focus on commercializing its proprietary APP technology by moving away from cannabis cultivation resources. Infusion Biosciences Inc will contribute additional funds to implement business transformation. It will also supply additional talent to support the transformation plan.

Business transformation strategy

As part of the light technology model, Sproutly will focus on generating revenues through establishing ingredient supply agreements, technology licensing, and partnership opportunities. It will scale down the cultivation of cannabis, which is capital intensive, and reduce cash burn.

Sproutly has recruited Dr. Anup Sen as Chief Executive Officer for implementing a business transformation plan. Anup is the first scientist to invent water soluble CBD in cannabis plants. Following the appointment of Dr. Anup, Keith Dolo is relinquishing the post of CEO. Keith will also step down from the board of Sproutly. He will act as an advisor to the Chairman. Keith said the company’s main target is to introduce unique products in the market by using APP Technology. Sproutly also slashed cash expenses by giving pink slips to operational and corporate staff.

Sproutly is adopting the new business strategy because of the operational challenges and headwinds in the industry. Prohibitive costs associated with cannabis cultivation have forced the company to change its business strategy.

Commercializes APP technology

Sproutly will focus on APP technology commercialization through formulation, production, and the sale of ingredients by using Bi-Natural Oils and water-soluble cannabinoids. The company will use the licensed manufacturers’ distribution networks and its existing infrastructure to realize its revised plan. Sproutly has faced bottlenecks in introducing cannabis 2.0 products because it has earmarked human resources and significant capital for cannabis cultivation.

Adopts cost-cutting measures

Sproutly has reduced the employees by 75% to reduce costs and reduce cannabis cultivation. It has eased the capital requirements for Sproutly and pursues other strategic alternatives. The company will get the support of six key personnel of Infusion Biosciences to assist in its daily operations.

Infusion Biosciences’s key executives have helped Sproutly in obtaining licenses for APP technology and in forming partnerships in the US. Sproutly also expects to expedite its commercialization efforts with the help of these executives.

Continue Reading


Aleafia Health Inc (OTCMKTS:ALEAF) Reports An Astonishing 2,486% Rise In Q1 2020 Revenues



Aleafia Health Inc (OTCMKTS:ALEAF) has reported revenues of $14.59 million in Q1 2020. It is an increase of 2,486% compared to the same period last year and a 143% increase compared to the previous quarter.

Reports solid growth for the fifth consecutive quarter

Geoffrey Benic, Chief Executive Officer of Aleafia, said the company achieved a breakthrough in Q1 2020 on the backdrop of sustainable and disciplined growth. As it builds the cannabis wellness and health ecosystem, the company gives importance to the patient-centric approach. It is the fifth consecutive quarter to report solid growth.

Expects to introduce new cannabis 2.0 products in H2

Aleafia expects to introduce new cannabis 2.0 products tailored for the wellness and health consumers in H2, 2020. Its active registered patient count has surged to 10,983 as of March 31, 2020, from 10,249 as of December 31, 2019.

Key achievements in Q1 2020

Aleafia on March 26, 2020, announced plans to introduce direct-to-door medical cannabis delivery service to the registered patients. It is a contactless and safe delivery mechanism for the patients. Therefore, Aleafia eliminates the need for collecting the products from post boxes and post offices.

Achievements after Q1 2020

According to the announcement on May 1, 2020, Glenn Washer and Rhonda Lawson will be appointed to the board with effect from May 16, 2020. It is on the backdrop of the resignation of the existing directors – Bill Stewart, and Raf Souccar with effective from May 15, 2020. Julian Fantino, Chairman, has also resigned from the board.

Aleafia has temporarily shut down its physical offices of the education centers and cannabis clinics across the nation since March 16, 2020, because of the ongoing coronavirus crisis. The company is completing the patient consultations via its virtual clinics.

To maintain long term success, the company maintains a diversified portfolio of differentiated and high-quality product formats. The company will use in-house facilities to manufacture cannabis 2.0 products and satisfy the demand in the medical and adult-use cannabis markets in Canada. It will also supply cannabis 2.0 products in markets worldwide where legally permitted.

Aleafia Farms Inc, a wholly-owned subsidiary of Aleafia, has secured an amended license from Health Canada on May 12, 2020, for the outdoor cultivation at its Port Perry Facility.

Continue Reading

Whats Hot